c o r r e s p o n d e n c e
Combination Antifungal Therapy for Cryptococcal Meningitis
To the Editor: In the trial of combination therapy for cryptococcal meningitis in patients with human immunodeficiency virus infection, Day et al. (April 4 issue) 1 found a survival benefit associated with 2 weeks of therapy with amphotericin B and flucytosine as compared with amphotericin B monotherapy. The results of this trial reinforce the treatment combination as the standard per current guidelines. 2,3 In locations where amphotericin B therapy is not feasible, flucytosine is recommended in combination with fluconazole. 2-4 However, the availability of flucytosine worldwide remains grossly inadequate.
Flucytosine is currently unregistered and unavailable in most of Asia and Africa, where the disease burden is greatest. 5 Even though flucytosine is a simple, orally administered, off-patent drug, only two manufacturers have been approved by the Food and Drug Administration: the originator company, Meda Pharmaceuticals, and the generic manufacturer, Sigmapharm Laboratories. The lack of data about disease burden, concerns regarding toxicity, and high drug costs due to a lack of competition have contributed to a market 
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The Authors Reply: We agree with Loyse et al. that increasing access to flucytosine could reduce deaths from cryptococcal meningitis. In our study, flucytosine levels were not monitored, but patients had regular blood counts and electrolyte and creatinine measurements. We showed that in a resource-constrained setting, in combination with amphotericin B, flucytosine can be used safely and increases both survival and fungal clearance. Patients receiving the combination treatment had similar rates of adverse events as those receiving amphotericin B monotherapy. Fluconazole combined with flucytosine, recommended as second-line treatment by the WHO, is an attractive treatment for cryptococcal meningitis because of ease of administration. 1 Fluconazole is cheaper than amphotericin B and has a favorable toxicity profile. However, amphotericin B-sparing combinations consistently show lower rates of yeast clearance from cerebrospinal fluid -early fungicidal activity -than those containing amphotericin B. 2 Bicanic and colleagues found that early fungicidal activity was closely correlated with survival. 3 Therefore, in addition to improving access to flucytosine, it is imperative that stakeholders work to improve the avail-ability of, and the capacity to safely administer, amphotericin B. 
